[Nature] Scientists dissected the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group, identifying the etiologies and mutational processes that drive the genomic and clinical heterogeneity of prostate cancer.

[Nature Cancer] Researchers found that oral administration of Nakaseomyces glabratus to castrated mice accelerated prostate cancer progression by promoting infiltration and activation of polymorphonuclear myeloid-derived suppressor cells.

[Nature Communications] Investigators showed that genetic loss of NCOA6 accelerates tumor growth in human pancreatic cancer xenografts, induces prostate tumorigenesis in mice, and cooperates with Pten haploinsufficiency to drive aggressive metastatic pancreatic cancer.

[Proceedings of the National Academy of Sciences of the United States of America] The authors established isogenic pancreatic cancer cell lines harboring the androgen receptor (AR) with a minimal length of CAG repeats and found that this AR variant exhibits attenuated response to AR-targeted therapies with markedly enhanced protein stability, expanded chromatin binding, and a reprogrammed transcriptional profile.

[Cell Death & Differentiation] Scientists showed that the PGC1α/ERRα complex reduces the protein levels of Hypoxia Inducible transcription Factor alpha in pancreatic cancer, providing a new component to the tumor-suppressive activity of the PGC1α/ERRα complex.

[Oncogene] Researchers identified BIRC6-AS1/BIRC6 as a significant contributor to abiraterone resistance in pancreatic cancer. They found depletion of either enhanced the sensitivity of pancreatic cancer cells to abiraterone in both in vitro and in vivo settings.

[Bioscience Reports] The authors investigated the expression and function of dipeptidyl peptidase-4 (DPP4) in androgen-sensitive and castration-resistant prostate cancer models.

[Molecular and Cellular Biochemistry] Investigators reported the biological effects of a sulfonamide-chalcone hybrid in the PC-3 prostate cancer cell line under standard culture conditions and nutrient deprivation.

[Cellular Signalling] Scientists comprehensively discuss the metabolic network, regulatory mechanism, and current challenges of castration-resistant prostate cancer.

[Janux Therapeutics] Janux Therapeutics, Inc. announced that the first patient has been dosed in the Phase I clinical trial evaluating JANX013, a novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer.

[Advanced Science] The authors identified that KRAS mutations act as drivers mediating an aberrant epitranscriptome in colorectal cancer. They showed pharmacological blockades that could boost efficacy of KRAS inhihbitors.

[Autophagy] Researchers unveiled a conserved effector-triggered immunity guard system in Caenorhabditis elegans and human intestinal epithelial cells that couples pore-forming toxins damage sensing to comprehensive epithelial recuperation.